In particular, the effects of growth hormone secretagogues, myostatin/activin pathway inhibitors, and biological agents already and progressively used in COPD (e.g., anti–IL-5 or anti–IL-4R therapies) on skeletal muscle structure and function deserve dedicated investigation. This evidence concerns the gene MSTN and chronic obstructive pulmonary disease.